ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and/or legal heir(s) of the registered shareholder(s) on 25th May, 2022. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Alembic Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here ALEMBIC LTD. - 506235 - Declaration Of Voting Results Of The Postal Ballot
Pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and above referred Postal Ballot Notice, we would like to inform you that the following special resolution has been passed by the members of the Company with requisite majority: 1. Re-appointment of Mrs. Malika Amin (DIN: 00242613) as Managing Director and Chief Executive Officer of the Company. The aforesaid resolution is deemed to have been passed effectively on the last date specified for remote e-voting i.e. 20th May, 2022. Please find enclosed herewith the Voting Results of Postal Ballot along with Scrutinizer's Report in this regard. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Disclosure On Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosures Requirements) Regulations, 2015 ('Listing Regulations, 2015')
With reference to the captioned matter, we would like to inform that pending the release of XBRL template in the new format prescribed by SEBI vide its Circular dated 22nd November, 2021 on Disclosure obligations of listed entities in relation to Related Party Transactions and based on the verbal guidance provided by the stock exchanges, we enclose herewith scanned copy of disclosures on Related Party Transactions for the half year ended 31st March, 2022. Please note that out of abundant precaution, we had filed the disclosures in old XBRL format on 13th May, 2022. However, as and when the updated template is released by the stock exchanges, we will again upload the said disclosures in XBRL. We request you to kindly take the above on records. ALEMBIC LTD. - 506235 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please find enclosed herewith the Annual Secretarial Compliance Report issued by M/s. Samdani Shah & Kabra, Practicing Company Secretaries, for the financial year ended 31st March, 2022. We request you to kindly take the same on record.
Alembic gets final USFDA nod for medication to treat bronchoconstriction
Alembic Pharmaceuticals Ltd on Wednesday said it has received final approval from the US health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial, the company said in a statement. The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD), Brovana inhalation solution, 15 mcg/2 mL, of Sunovion Pharmaceuticals Inc, it added. Arformoterol Tartrate inhalation solution is indicated for long-term, twice daily administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, the company said. This ANDA has... ALEMBIC LTD. - 506235 - Board recommends Dividend
Alembic Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 05, 2022, inter alia, has recommended Dividend of Rs. 1.80/- (90%) per Equity Share having face value of Rs. 2 each for the year ended March 31, 2022, subject to approval of Shareholders at the ensuing Annual General Meeting. ALEMBIC LTD. - 506235 - Audited Financial Results Of The Company For The Financial Year Ended 31St March, 2022
The Board of Directors of Alembic Limited at its meeting held today has inter alia: 1. Approved the Audited Financial Results of the Company for the financial year ended 31st March, 2022. 2. Recommended Dividend of Rs. 1.80/- (90%) per Equity Share having face value of Rs. 2 each for the year ended 31st March, 2022, subject to approval of Shareholders at the ensuing Annual General Meeting. We enclose the following: A. (i) Consolidated Audited Financial Results (ii) Consolidated Statement of Assets and Liabilities (iii) Consolidated Cash Flow Statement B. (i) Standalone Audited Financial Results (ii) Standalone Statement of Assets and Liabilities (iii) Standalone Cash Flow Statement C. Auditor's Report on Consolidated and Standalone Financial Results The Statutory Auditors of the Company has issued audit report with unmodified opinion on the Audited Financial Results of the Company The time of commencement of the Board Meeting was 4:00 p.m. and the time of conclusion was 5:10 p.m.
